Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Impairment expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Zomedica

Zomedica Corp. operates as a veterinary health company, which engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. It offers products for dogs and cats by focusing on the unmet needs of clinical veterinarians. Its TRUFORMA biosensor platform is designed to assist practitioners in the diagnosis of complex conditions. The company was founded by Gerald L. Solensky. on January 7, 2013 and is headquartered in Ann Arbor, MI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Zomedica reports revenue growth and product advancements amidst profitability challenges

Zomedica's 2022 performance reflects revenue growth and product advancements, though challenges in profitability persist. The company's strategic focus on companion animal healthcare presents growth opportunities through innovation and market stability. Addressing expense management, stock stability, and leveraging market trends will be key for Zomedica's future success.

Zomedica reports robust Q1 earnings, eyes global equine market

Zomedica's Q1 2023 showcased strong revenue growth, particularly driven by TRUFORMA and international sales.
The company's focus on maintaining margins, expanding marketing efforts, and targeting global equine markets positions it for future success.
Challenges include the closure of the cancer assay program and operational hurdles in achieving the 70% gross margin target.
Opportunities lie in the launch of new assays, international expansion, and investor engagement beyond quarterly updates.

Zomedica reports robust Q2 earnings, eyes international expansion and product launches

Zomedica's Q2 performance reflects strong revenue growth and strategic investments for future profitability.
Despite challenges like increased OpEx and lower margins, the company is focused on long-term growth through product launches and market expansion.
Opportunities lie in international market exploration, upcoming product launches, and investor engagement strategies.

Zomedica reports record revenues, eyes global expansion amidst stock challenges

Zomedica's Q3 performance reflects strong revenue growth and strategic acquisitions, despite facing challenges like potential delisting and net losses.
The company's focus on new product launches, international expansion, and partnerships presents opportunities for future growth and market diversification.
Overall, Zomedica aims to drive towards cash flow breakeven by leveraging innovative products and maintaining a strong liquidity position.

Zomedica reports record revenues, eyes profitability through strategic growth

Zomedica's strong financial performance in Q4 2023 and full-year results, coupled with a robust cash position and strategic growth initiatives, position the company for future success.
While facing challenges related to compliance requirements and integration costs, Zomedica's focus on innovation, market expansion, and profitability goals present opportunities for sustained growth.
By balancing operational efficiency, product development, and financial discipline, Zomedica aims to drive revenue growth, enhance market presence, and deliver long-term value to shareholders.

Zomedica reports revenue growth and strong cash position in Q1

Zomedica's Q1 2024 performance showed revenue growth driven by key segments, strong cash position, and focus on operational efficiency. The company faces challenges in managing expenses and achieving aggressive revenue targets. Opportunities lie in expanding product lines, international sales, and maintaining financial strength.

Zomedica reports Q2 revenue growth amidst challenges and opportunities

Zomedica's Q2 performance showed revenue growth but with challenges in sales force and noncash charges.
Strengths include achieving milestones and expanding facilities, while opportunities lie in international expansion.
The company faces the task of managing cash burn and finding a new CFO.
Expectations for the second half of 2024 include revenue growth and operational focus.

Zomedica reports record Q3 revenue, eyes global expansion opportunities

Zomedica's Q3 2024 performance showcased revenue growth, margin strength, and cost reduction efforts, positioning the company for future profitability. Strategic international partnerships and product innovations underscore growth potential.
While challenges in achieving profitability persist, Zomedica's focus on operational efficiency and global expansion presents opportunities for sustained growth. Addressing investor inquiries and executing on strategic initiatives will be key to unlocking future value.
With a solid cash position, ongoing product enhancements, and expansion into new markets, Zomedica is poised for growth. Clear communication on financial targets, operational milestones, and strategic direction will be crucial for investor confidence and market success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The hype surrounding ZOM stock has worn off, and it's now time for the company to prove its value through its sales numbers. The post Zomedica Pharmaceuticals Has to Prove Itself to Long-Term Investors appeared first on InvestorPlace.

Zomedica Pharmaceuticals Has to Prove Itself to Long-Term Investors

Zomedica is good value looks like it will go on the acquisition warpath. ZOM stock is worth between $1.11 and $1.61, or $1.36 on average, providing an average 20% ROI over 2 years.

Zomedica Is Good Value and May Be Worth $1.36 — Or More

ZOM stock has spiked sharply this year, but a recent price pullback could signal an ideal entry point for pet care market investors. The post Zomedica Is Surprisingly Cheap Even as Commercialization Commences appeared first on InvestorPlace.

Zomedica Is Surprisingly Cheap Even as Commercialization Commences

Applied Genetic Technologies

Genius Brands

Globalstar

Ideanomics Inc

Cenntro Electric Group

Nokia

Penny stocks are not usually on lists of must-buy stocks, but that does not mean these companies cannot explode in the coming weeks. The post 7 Penny Stocks To Watch Before They Pop Due to Reddit Users appeared first on InvestorPlace.

7 Penny Stocks To Watch Before They Pop Due to Reddit Users

AmerisourceBergen

Chewy

Covetrus Inc

Elanco Animal Health Inc

Freshpet

General Mills

Heska

IDEXX Laboratories

Merck

Nestle SA

Proshares Pet Care ETF

Patterson Companies

PetIQ

J. M. Smucker

Unicharm Corp

Petco Health and Wellness

Zoetis

The physiological and psychological benefits that pets give us are meaningful. COVID has amplified our appreciation of this. Anticipating 6% annual growth until 2030 may be conservative, even across developed markets.

Overview Of Opportunities In Animal Companionship: A $200B Industry Growing At 6.1% Annually

Sesen Bio Inc.

Which biotech penny stocks are on your watchlist as Covid comes to an end? The post Top Biotech Penny Stocks to Buy?

Top Biotech Penny Stocks to Buy? Check These Small-Caps Out

Atossa Genetics

Reddit penny stocks are back in focus as AMC stock rises; which 3 are you watching? The post Reddit Penny Stocks to Buy?

Reddit Penny Stocks to Buy? 3 Small-Caps For Your Summer Watchlist

You may like ZOM stock as a pet lover, but not for its fundamentals, nor its valuation until it starts having credible financial results. The post Zomedica's Risks Are Too Big to Ignore appeared first on InvestorPlace.

Zomedica's Risks Are Too Big to Ignore

Zomedica has promising growth potential, but its high share count makes ZOM stock a risky investment. Here's what investors should know.

Zomedica's High Share Count Creates Challenges for ZOM Stock

Another pullback in ZOM stock will put this long-term speculative play's odds in your favor if its Truforma product catches on. The post Zomedica Stock Will Be Worth The Risk After Another Drop appeared first on InvestorPlace.

Zomedica Stock Will Be Worth The Risk After Another Drop

The skeptics might misinterpret the company's first-quarter revenue data, but a deeper dive should uncover reasons to hold on to ZOM stock. The post Right-Priced Zomedica Could Be an Investor's Best Friend appeared first on InvestorPlace.

Right-Priced Zomedica Could Be an Investor's Best Friend

Ashford Hospitality Trust

Vertex Energy

Reopening penny stocks are in focus; here's 3 to watch right now The post Hot Penny Stocks To Buy Right Now? 3 Reopening Stocks To Watch appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Hot Penny Stocks To Buy Right Now? 3 Reopening Stocks To Watch

Cinedigm

LAIX Inc - ADR

Pieris Pharma

Best Robinhood penny stocks for Summer 2021? Check these 4 out The post 4 Robinhood Penny Stocks to Watch in Summer 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Robinhood Penny Stocks to Watch in Summer 2021

Zomedica's Truforma machine has entered the vet equipment market, which is consolidating rapidly. That means results on whether this can work should come quickly for ZOM stock investors.

Bets on Zomedica's In-Office Vet Test Could Payoff or Bust by Year-End

ZOM stock trades below $1 as investors wait to see if recent changes to the company's business model along with potential acquisitions can be a catalyst for revenue. The post Is Zomedica Making a Change For the Better?

Is Zomedica Making a Change For the Better?

SNDL Inc.

Snowflake

This isn't where you'd expect the brightest and most successful investors to put their money to work.

3 Surprising Stocks Money Managers Bought Hand Over Fist in Q1

Zomedica is testing its support levels at current prices. What does the maker of diagnostic equipment need to do to get ZOM stock back to $1?

Zomedica Stock Can Return to a Dollar If It Focuses on Just One Thing

ZOM stock makes for a better trading vehicle than an investment in spite of their noble effort to heal. It needs to hold recent lows or else.

Zomedica Stock Is At Serious Risk Unless Bulls Commit

Or will speculation lead to major disappointment?

Could Zomedica Be a Millionaire-Maker Stock?

Zomedica has lost the fast money crowd, but what remains could be a stronger longer-term play in ZOM stock. The post Why Zomedica Doesn't Need Reddit appeared first on InvestorPlace.

Why Zomedica Doesn't Need Reddit

A new executive will oversee the company's growth initiatives.

Why Zomedica Stock Popped Today

Centennial Resource Development

Hot penny stocks to watch as Bitcoin and DogeCoin show high volatility The post 3 Penny Stocks To Watch Amidst Bitcoin & DogeCoin Price Volatility appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Penny Stocks To Watch Amidst Bitcoin & DogeCoin Price Volatility

Former Elanco Animal Health, Johnson & Johnson, Intuitive Surgical, and Enteromedics Business Development Executive Joins Team to Support Growth Opportunities

Zomedica Hires Vice President Business Development to Lead Acquisition and Licensing Efforts

The bull market has certainly made new investors look like geniuses, as usual. But now is the true test and ZOM stock isn't likely to pass.

Zomedica Stock Will Burn You as High-Growth Stocks Start to Flag

The share price of the Ann Arbor, Michigan-based animal health company has now gone from a pullback and into a steep decline. Since March 15th, ZOM stock has fallen 68% and is now below the $1 threshold at just $0.79 per share.

News for Zomedica Stock (ZOM)